FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

Retrieved on: 2020-11-25 21:56:15

Tags for this article:

Click the tags to see associated articles and topics

FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma. View article details on hiswai:

Excerpt

DANYELZA is a humanized, <b>monoclonal antibody</b> that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived ...

Article found on: pipelinereview.com